STAT3 and breast cancer: In vivo, bardoxolone methyl treatment initiated 1 day after tumor implantation completely eradicated 4T1 breast cancer growth and lung metastases in mice, and significantly inhibited tumor progression when treatment began 5 days post-implantation, suggesting that bardoxolone methyl may offer therapeutic potential in breast cancer treatment, potentially through the inactivation of STAT3 signaling [71].